Nanomedicine and drug delivery to the retina: current status and implications for gene therapy

被引：0

作者：

Mohamed Tawfik

Fang Chen

Jeffrey L. Goldberg

Bernhard A. Sabel

机构：

[1] Otto-Von-Guericke University,Institute of Medical Psychology, Medical Faculty

[2] Stanford University School of Medicine,Spencer Center for Vision Research, Byers Eye Institute

来源：

Naunyn-Schmiedeberg's Archives of Pharmacology | 2022年 / 395卷

关键词：

Retinal drug delivery; Nanomedicine; Retina; Retinal diseases; Gene therapy; Nanoparticles;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Blindness affects more than 60 million people worldwide. Retinal disorders, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, are the leading causes of blindness. Finding means to optimize local and sustained delivery of drugs or genes to the eye and retina is one goal to advance the development of new therapeutics. Despite the ease of accessibility of delivering drugs via the ocular surface, the delivery of drugs to the retina is still challenging due to anatomic and physiologic barriers. Designing a suitable delivery platform to overcome these barriers should enhance drug bioavailability and provide a safe, controlled, and sustained release. Current inventions for posterior segment treatments include intravitreal implants and subretinal viral gene delivery that satisfy these criteria. Several other novel drug delivery technologies, including nanoparticles, micelles, dendrimers, microneedles, liposomes, and nanowires, are now being widely studied for posterior segment drug delivery, and extensive research on gene delivery using siRNA, mRNA, or aptamers is also on the rise. This review discusses the current state of retinal drug/gene delivery and highlights future therapeutic opportunities.

引用

页码：1477 / 1507

页数：30

共 732 条

[1]

Ackl P(2017)World blindness visual impairment: despite many successes the problem is growing Community Eye Health 30 71-73

[2]

Resnikoff S(1994)Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy A J Ophthalmol 118 445-450

[3]

Bourne R(2013)In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry Mol Pharm 10 249-260

[4]

Adamis AP(2020)Neuroscience in the blink of an eye: using the retina to understand the brain BIOCHEM 42 18-24

[5]

Miller JW(2008)Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice J Clin Investig 118 1955-1964

[6]

Bernal MT(2012)The molecular basis of retinal ganglion cell death in glaucoma Prog Retin Eye Res 31 152-181

[7]

Albertazzi L(2019)Self-assembling topical nanomicellar formulation to improve curcumin absorption across ocular tissues AAPS PharmSciTech 20 1-16

[8]

Gherardini L(2016)Targeting VEGF in eye neovascularization: what’s new?: A comprehensive review on current therapies and oligonucleotide-based intervntions under development Pharmacol Res 103 253-269

[9]

Brondi M(2012)Mechanisms of age-related macular degeneration Neuron 75 26-39

[10]

Albrecht NE(2017)The future looks brighter after 25 years of retinal gene therapy Hum Gene Ther 28 982-987

← 1 2 3 4 5 6 7 8 9 10 →